← TransMedics Group, Inc.
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue: | $14.7m | $25.8m | $25.6m | $30.3m | $93.5m | $241.6m | $441.5m | $605.5m | $668.5m | |
| Total cost of revenue | $7.3m |
$9.7m
+33.75%
|
$9.0m
-7.57%
|
$9.1m
+1.10%
|
$28.2m
+209.65%
|
$87.5m
+210.53%
|
$179.5m
+105.03%
|
$242.7m
+35.23%
|
— | |
| Gross profit | $5.7m |
$13.9m
+141.77%
|
$16.6m
+20.00%
|
$21.2m
+27.20%
|
$65.3m
+208.48%
|
$154.1m
+136.08%
|
$262.1m
+70.08%
|
$362.8m
+38.43%
|
$392.3m
+8.14%
|
|
| Acquired in-process research and development expenses | — | — | — | — | — | $27.2m | — | — | — | |
| Selling, general and administrative | $12.3m | $23.6m | $24.2m | $38.3m | $69.9m | $119.6m | $168.6m | $185.2m | $210.8m | |
| Total operating expenses | $26.0m | $43.5m | $43.0m | $60.6m | $96.7m | $182.8m | $224.6m | $254.2m | $310.7m | |
| Interest expense | ($2.7m) | ($4.4m) | ($4.0m) | ($3.9m) | ($3.7m) | ($10.8m) | ($14.4m) | ($13.8m) | $21.2m | |
| Interest income and other income (expense), net | — | — | — | — | ($1.0m) | $12.8m | $12.7m | $12.7m | $14.9m | |
| Total other income (expense), net | ($3.5m) | ($3.9m) | ($2.3m) | ($4.8m) | ($4.7m) | $2.1m | ($1.7m) | ($1.1m) | — | |
| Income (loss) before income taxes | — | — | ($28.7m) | ($44.2m) | ($36.2m) | ($26.7m) | $35.8m | $107.5m | — | |
| (Provision) benefit for income taxes | — | — | — | ($36k) | ($66k) | $1.6m | $316k | $82.8m | — | |
| Net income (loss) | ($23.8m) |
($33.5m)
-41.21%
|
($28.7m)
+14.31%
|
($44.2m)
-53.80%
|
($36.2m)
+18.06%
|
($25.0m)
+30.92%
|
$35.5m
+241.70%
|
$190.3m
+436.58%
|
$151.7m
-20.28%
|
|
| Net income (loss) per share, basic | — | — | ($1) | ($2) | ($1) | ($1) | $1 | $6 | $151.7m | |
| Net income (loss) per share, diluted | ($17) | ($2) | ($1) | ($2) | ($1) | ($1) | $1 | $5 | $151.7m | |
| Weighted average common shares outstanding, basic | — | — | 24.7m | 27.6m | 29.6m | 32.5m | 33.2m | 34.0m | — | |
| Weighted average common shares outstanding, diluted | — | — | 24.7m | 27.6m | 29.6m | 32.5m | 35.2m | 40.5m | — | |
| Research, development and clinical trials | $13.7m | $19.9m | $18.8m | $22.3m | $26.8m | $36.1m | $56.0m | $69.1m | $92.5m | |
| Income (loss) from operations | ($20.2m) |
($29.6m)
-46.28%
|
($26.4m)
+10.87%
|
($39.4m)
-49.44%
|
($31.4m)
+20.27%
|
($28.7m)
+8.62%
|
$37.5m
+230.53%
|
$108.6m
+189.59%
|
$81.6m
-24.84%
|